Publication:
Future treatments in hypertension: can we meet the unmet needs of patients?

dc.contributor.coauthorLaffin, Luke
dc.contributor.departmentSchool of Medicine
dc.contributor.kuauthorKanbay, Mehmet
dc.contributor.kuauthorUçku, Duygu
dc.contributor.kuauthorTanrıöver, Cem
dc.contributor.kuauthorÇöpür, Sidar
dc.contributor.schoolcollegeinstituteSCHOOL OF MEDICINE
dc.date.accessioned2025-01-19T10:31:59Z
dc.date.issued2023
dc.description.abstractThe prevalence of arterial hypertension is approximately 47% in the United States and 55% in Europe. Multiple different medical therapies are used to treat hypertension including diuretics, beta blockers, calcium channel blockers, angiotensin receptor blockers, angiotensin converting enzyme inhibitors, alpha blockers, central acting alpha receptor agonists, neprilysin inhibitors and vasodilators. However, despite the numerous number of medications, the prevalence of hypertension is on the rise, a considerable proportion of the hypertensive population is resistant to these therapeutic modalities and a definitive cure is not possible with the current treatment approaches. Therefore, there is a need for novel therapeutic strategies to provide better treatment and control of hypertension. In this review, our aim is to describe the latest developments in the treatment of hypertension including novel medication classes, gene therapies and RNA-based modalities.
dc.description.indexedbyWOS
dc.description.indexedbyScopus
dc.description.indexedbyPubMed
dc.description.publisherscopeInternational
dc.description.sponsoredbyTubitakEuN/A
dc.description.volume115
dc.identifier.doi10.1016/j.ejim.2023.06.008
dc.identifier.eissn1879-0828
dc.identifier.issn0953-6205
dc.identifier.quartileQ1
dc.identifier.scopus2-s2.0-85163358005
dc.identifier.urihttps://doi.org/10.1016/j.ejim.2023.06.008
dc.identifier.urihttps://hdl.handle.net/20.500.14288/26337
dc.identifier.wos1077165000001
dc.keywordsHypertension
dc.keywordsHypertension management
dc.keywordsAldosterone synthase inhibitors
dc.keywordsDual endothelin antagonists
dc.keywordsGene-based therapies in hypertension
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofEuropean Journal of Internal Medicine
dc.subjectMedicine
dc.titleFuture treatments in hypertension: can we meet the unmet needs of patients?
dc.typeReview
dspace.entity.typePublication
local.contributor.kuauthorKanbay, Mehmet
local.contributor.kuauthorÇöpür, Sidar
local.contributor.kuauthorTanrıöver, Cem
local.contributor.kuauthorUçku, Duygu
local.publication.orgunit1SCHOOL OF MEDICINE
local.publication.orgunit2School of Medicine
relation.isOrgUnitOfPublicationd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isOrgUnitOfPublication.latestForDiscoveryd02929e1-2a70-44f0-ae17-7819f587bedd
relation.isParentOrgUnitOfPublication17f2dc8e-6e54-4fa8-b5e0-d6415123a93e
relation.isParentOrgUnitOfPublication.latestForDiscovery17f2dc8e-6e54-4fa8-b5e0-d6415123a93e

Files